Zoom Meeting

Advanced Registration Required: Register Here

In placebo-controlled trials of patients with type 2 diabetes and risk factors, selected SGLT2 inhibitors and GLP-1 agonists have been shown to reduce the risk of major cardiovascular events and may have the additional benefit of weight loss. This talk will present two ongoing retrospective cohort studies, one using national administrative claims data to examine the effect of high out-of-pocket costs on initiation of these newer drug classes in patients with T2D and established CVD, and another reporting changes in body weight 72 weeks after initiating a GLP-1 agonist among a cohort of over 2,000 patients receiving care at a large academic medical center. The presentation will also include the design and rationale for a multi-center randomized control trial comparing a long-acting insulin analogue against human insulin for youth with type 1 diabetes living in low-resource settings.